Nomura Securities Maintains a 'Buy' on Danaher (DHR); Q4 Review

February 1, 2012 10:33 AM EST
Get Alerts DHR Hot Sheet
Price: $201.65 -0.4%

Rating Summary:
    30 Buy, 10 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 12 | Down: 21 | New: 20
Join SI Premium – FREE
Nomura Securities maintains a 'Buy' on Danaher (NYSE: DHR) price target of $59.00.

Analyst, Shannon O'Callaghan, said, "Segment OP beat us by $0.01 and EPS beat us by $0.02 on a continuing ops basis, with organic growth and margins both slightly better. Organic growth of 4% beat our 3.2% estimate (and guide for less than 4%) driven by a better December, which does not appear to be pull-forward given solid trends in January. 1Q guide of $0.66- $0.71 compares to our $0.70 and consensus of $0.71. 2012 guide maintained at $3.20-$3.35 vs. our $3.35 and consensus of $3.30. Importantly, Beckman has now resolved both its sodium and glucose test issues, demonstrating significant quality improvements since joining Danaher despite a Troponin process that could take a while."

For an analyst ratings summary and ratings history on Danaher click here. For more ratings news on Danaher click here.

Shares of Danaher closed at $52.51 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Nomura